+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P12597(ADAMTS3 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P12597(ADAMTS3 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The ADAMTS3 (A Disintegrin and Metalloproteinase with Thrombospondin Motifs 3) antibody is a research tool targeting the ADAMTS3 protease, a member of the ADAMTS family involved in extracellular matrix (ECM) remodeling and proteolytic processing of bioactive molecules. ADAMTS3 is best known for its role in activating procollagen I and II through cleavage of their N-propeptides, a critical step in collagen fibril assembly. It also processes other ECM components, such as versican, and participates in lymphatic vessel development by cleaving VEGF-C, a key regulator of lymphangiogenesis. Mutations in ADAMTS3 are linked to human disorders like Hennekam syndrome, a rare autosomal recessive condition characterized by lymphedema and developmental abnormalities.

The ADAMTS3 antibody is primarily used in biomedical research to study the enzyme's expression, localization, and function in tissues, particularly in connective tissues, skin, and lymphatic systems. It aids in investigating ADAMTS3's involvement in pathological conditions, including fibrosis, osteoarthritis, and lymphatic dysplasia. Commercial ADAMTS3 antibodies are typically developed in rabbit or mouse hosts, targeting specific epitopes within its catalytic domain, disintegrin-like region, or thrombospondin motifs. Validation often includes Western blotting, immunohistochemistry, and knockout controls. Challenges in antibody development stem from structural complexity, including multiple domains and post-translational modifications. Reliable ADAMTS3 antibodies are crucial for elucidating its biological roles and exploring therapeutic strategies for related diseases.